Boston Scientific, Guidant Push Back Closing Date, Warn Of Merger Risks
This article was originally published in The Gray Sheet
Executive Summary
A one-week delay in the $27.2 mil. merger of Boston Scientific and Guidant will cause Boston Scientific to ante up penalty fees to Guidant shareholders
You may also be interested in...
Boston Scientific Wins Guidant Takeover Battle, Ending Fierce Bidding War
Boston Scientific faces the monumental task of integrating ICD-manufacturer Guidant following a $27.2 bil. acquisition victory over Johnson & Johnson on Jan. 25
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.